A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Meropenem-Vaborbactam (VABOMERE)

beta Lactamase Inhibitor class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2017-10-02
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
1 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Meropenem-Vaborbactam used for?

Meropenem-Vaborbactam is a beta Lactamase Inhibitor medication tracked in Medicare Part D.

Is there a generic for Meropenem-Vaborbactam?

No. Meropenem-Vaborbactam is brand-only with no generic equivalents currently in market.

How much does my plan pay for Meropenem-Vaborbactam?

NADAC pricing data not currently available for this drug.

Is Meropenem-Vaborbactam on the FDA shortage list?

No. Meropenem-Vaborbactam is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

beta Lactamase Inhibitor3 alternatives in D1
01
Amoxicillin and Clavulanate
Brand: AUGMENTIN ES-600
$0.049Lowest NADAC
8Generic mfrs
CY24 Part D spend
Compare →
02
Aztreonam and Avibactam
Brand: EMBLAVEO
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
03
Meropenem
Penem Antibacterial
$5.84Lowest NADAC
8Generic mfrs
$26.3MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.